Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round up of R&D news in brief

New ADHD drug edges closer to launch

US company Cephalon says it has received an approvable letter from the US Food and Drug Administration for a new drug to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. The drug, which would be sold in the US under the brand name Sparlon, would be co-marketed with a unit of Johnson & Johnson. Dr Chris Kratochvil, an associate psychiatry professor at the University of Nebraska Medical Centre said that although other ADHD drugs such as Novartis' Ritalin and Shire's Adderall were effective overall, doctors needed additional options because not all drugs were effective in individual patients.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...